Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119
Dean A. Wacker(Bristol-Myers Squibb (United States)), Jeffrey A. Robl(Bristol-Myers Squibb (Germany)), Steven C. Griffen(Io Therapeutics (United States)), Sarah E. Malmstrom(Bristol-Myers Squibb (United States)), Larisa Sereda(Bristol-Myers Squibb (United States)), Steven O’Connor(Bristol-Myers Squibb (United States)), Linda LaMarre(Bristol-Myers Squibb (United States)), Hong Cai(Shanghai Medical College of Fudan University), Chunyu K. Wu(Bristol-Myers Squibb (United States)), Stephanie Boehm(Bristol-Myers Squibb (United States)), Anjaneya Chimalakonda, Randolph Ponticiello(Bristol-Myers Squibb (United States)), Chiuwa E. Luk(Bristol-Myers Squibb (United States)), Karen A. Rossi(Bristol-Myers Squibb (United States)), Chen-Pin Hung(Bristol-Myers Squibb (United States)), Cuixia Chu(Bristol-Myers Squibb (United States)), Richard Wong(University of California San Diego), Gerry Everlof(Bristol-Myers Squibb (United States)), Jacob Zalaznick(Bristol-Myers Squibb (United States)), Zhenqiu Hong(Bristol-Myers Squibb (United States)), Rachel Zebo(Bristol-Myers Squibb (United States)), Yixin Li(Chongqing University), Michelle Lee(Pfizer (United States)), Li Xin(Bristol-Myers Squibb (United States)), Keith J. Miller(Bristol-Myers Squibb (United States)), John Krupinski(Bristol-Myers Squibb (United States)), Song‐Ping Han(Bristol-Myers Squibb (United States)), Ginger Wu(Bristol-Myers Squibb (United States)), Ying Wang(Chinese Academy of Sciences), Matthias Broekema(Bristol-Myers Squibb (United States)), Lisa Zhang(Bristol-Myers Squibb (United States)), Bradley A. Zinker(Abbott (United States))
Cited by 46
Related Papers
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
|Nature|2007|732
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice
|Proceedings of the National Academy of Sciences|2002|415
Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State
|The Journal of Clinical Endocrinology & Metabolism|2007|373